David Morris, MD, Division Chief

• medical school: Wright State University Boonshoft School of Medicine, Dayton, Ohio
• internship: Dayton Children's Hospital
• residency: Pediatrics - Wright State University, Dayton Children’s Hospital, Dayton, Ohio
• fellowship: Allergy and Immunology - University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
• board certification: Pediatrics, allergy and immunology

Morris, David (PI), AAAAI Fellow-In-Training Grant, Characterization of Eosinophil Progenitors in the Peripheral Blood of Pediatric Patients with Active Eosinophilic Esophagitis. July 2014-July 2015

• Schwartz, JT, Morris D, Collins MH, Rothenberg ME, Fulkerson PC; Eosinophil progenitor levels correlate with pathology in pediatric eosinophilic esophagitis, JACI (2019) Vol 143 (3), pages 1221-24
• Rosenberg CE, Mingler MK, Caldwell JM, Collins MH, Fulkerson PC, Morris D, Mukkada VA, Putnam PE, Shoda T, Wen T, Rothenberg, ME; Esophageal IgG4 Levels correlate with histopathic and transcriptomic features in eosinophilic esophagitis, Allergy (2018); 73:1892-1901
• Tuttle KL, Schneider TR, Henrickson S, Morris D, Abonia JP, Spergel J, Laidlaw T; Asprin-exacerbrated respiratory disease; not always "adult-onset", JACI: In Practice (2016) Vol. 4 (4) pages 756-758
• Morris D, Stucke E, Martin LJ, Abonia JP, Mukkada VA, Putnam PE, Rothenberg ME, Fulkerson P, Eosinophil progenitor levels are increased in active pediatric eosinophilic esophagitis, JACI (2016), 138 (3):915-918
• Miller RD, ......Morris D (44 of 63), High-density single-polymorphism maps of the human genome, Genomics (2005) August, 86 (2):117-26.
• Berberich SJ, Litteral V, Mayo LD, Tabesh D, Morris D, Mdm-2 Gene Amplification in 3T3L1 Preadipocytes, Differentiation (1999) May 64 (4):205-212.

• Compassionate Use Open-Label Study of Anti-IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome, Sub-Investigator, 2013-2016
• ARC: Oral Desnsitization to Peanut in Peanut-Allergic Children and Adults using Characterized Peanut Allergen (CPNA) Peanut Oral Immunotherapy (OIT) Safety Follow-On Study, Sub-Investigator, 2014-present
• A Double-Blind, Placebo-Controlled, Randomized Phase III Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy with ViaSkin(R) Peanut in Peanut-Allergic Children (PEPITES Study), Sub-Investigator, 2015-2016
• MTAX: A Phase 2 Study Multi Oral Immunotherapy in Multi Food allergic Patients to Test Tolerance, Sub-Investigator, 2015-present
• REGENERON Protocol R668-EE-1324: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Dupilumab in Adult Patients with Active Eosinophilic Esophagitis, Sub-Investigator, 2015-present
• CEGIR 7802: SOFEED Study: Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) followed by Swallowed Glucocoricoid Trial, Sub-Investigator, 2015-present
• PCORI diet study: Eosinophilic Esophagitis (EoE) Intervention Trail-Randomized 1 Food Elimination vs. 4 Food Elimination Diet followed by Swallowed Glucocorticoids, Sub Investigators 2015-present